JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

Benzinga Newsdesk www.benzinga.com Positive 83.8%

Neg 0% Neu 0% Pos 83.8%

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.